MorphiDex

MorphiDex®

Pain management A morphine with dextromethorphan, an NMDA receptor antagonist, for relieving severe CA pain Pros Faster onset of action, lasts 8 hrs. See Morphine.
References in periodicals archive ?
As previously announced, a Phase III long-term, double-blind crossover study of 77 patients suffering chronic pain demonstrated that MorphiDex delivers equal analgesic activity at approximately one-half the narcotic dose of morphine.
Algos submitted the full MorphiDex NDA on August 19, 1998, containing data from 14 separate studies involving more than 1,500 patients.
Algos has exclusive patent licenses for a number of narcotic and non-narcotic NMDA-receptor antagonist combinations, including MorphiDex.
Algos also stated that in a Phase III study involving the open label treatment of 250 chronic pain patients who were converted from their previous opiate to MorphiDex over a period of approximately two weeks, the patients rated MorphiDex significantly superior to their previous analgesic (p=0.
Algos submitted the MorphiDex New Drug Application (NDA) on August 19th of this year containing data from fourteen separate studies involving more than 1,500 patients.
A long-term, multi-dose, cross-over study of chronic pain demonstrated that MorphiDex delivers equal analgesic activity at one-half the narcotic dose of morphine.
Patients treated with MorphiDex expressed strong satisfaction ratings for the new analgesic over existing narcotics such as morphine, fentanyl and hydromorphone.
MorphiDex is the first of a series of new analgesics being developed by Algos to treat pain sufferers.
I am truly pleased with the quality of the work and the dedication of the Algos team in completing the New Drug Application for MorphiDex," said John W.